Moderate riskFDA DrugClass II

Endo USA buprenorphine injection recalled for particulate matter contamination

Endo USA is recalling certain batches of buprenorphine hydrochloride 0.3 mg/mL injection due to the presence of particulate matter identified as buprenorphine free base in the vials. The affected lots are 84132 (expiration 02/28/2027) and 87693 (expiration 03/31/2027). No injuries have been reported.

From the FDA notice · Read the official notice ↗

Update since first reported

  • Nov 1, 2026Hazard description updated

What to do

  1. Check your buprenorphine vials against the lot numbers and expiration dates listed in this recall.
  2. Do not use vials from lot 84132 or 87693.
  3. Contact your pharmacy or healthcare provider for a replacement or alternative.
  4. Report any use of recalled product to the FDA MedWatch program or your healthcare provider.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Units affected
34,293 vials
Illnesses reported
None reported
Manufactured in
870 Parkdale Rd, Rochester, MI, United States
Classification
Class II
Recall number
D-0527-2026

In the FDA's words

Description
Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05. Crystallization; identified as Buprenorphine free base Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027 Distribution: USA Nationwide Affected quantity: 34,293 vials
Hazard
Crystallization; identified as Buprenorphine free base

Related topics

ParticulateDrugsSold nationwideMore from FDA Drug